Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine
Conditions
Interventions
Tx360
Locations
11
United States
Yale University
New Haven, Connecticut, United States
New England Institute for Clinical Research
Stamford, Connecticut, United States
Eisenhower Army Medical Center
Fort Gordon, Georgia, United States
Crescent City Headache and Neurology Centre
Chalmette, Louisiana, United States
MedVadis Research
Watertown, Massachusetts, United States
Clinvest Research, LLC
Springfield, Missouri, United States
Start Date
September 20, 2017
Primary Completion Date
November 15, 2023
Completion Date
December 29, 2023
Last Updated
January 5, 2024
NCT04715685
NCT06617832
NCT05232942
NCT07373275
NCT06083571
NCT03472092
Lead Sponsor
Tian Medical Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions